NMN Increased NAD⁺ in a Human Trial. But What Happened to Walking and Sleep?
NMN has become one of the most talked-about compounds in longevity research, largely because it helps the body produce NAD⁺, a molecule essential for cellular metabolism.
But increasing NAD⁺ is only part of the story.
Researchers also want to know whether NMN supplementation can influence outcomes people actually notice, including physical performance and sleep quality.
A 2024 randomized, double-blind, placebo-controlled trial investigated these questions in 60 older adults. Participants received 250 mg of NMN daily or a placebo for 12 weeks.
The researchers reported increased blood NAD⁺ and related metabolites in the NMN group. They also found differences in a four-meter walking test and selected sleep-quality measures.
However, the study's primary stepping-test outcome did not show a statistically significant difference between the NMN and placebo groups.
That detail matters.
The findings provide an interesting look at how NMN affects human NAD⁺ biology, but they do not establish that NMN reverses aging or improves walking and sleep for everyone.
So what did the trial actually prove, and what remains uncertain?
Let's examine the results and explore what they mean when evaluating an NMN supplement.
First, What Is NAD⁺?
NAD⁺ stands for nicotinamide adenine dinucleotide.
It is a coenzyme found throughout the body and plays an essential role in numerous cellular processes.
One of its main functions involves redox reactions, which help cells transfer electrons during the metabolic processes used to extract energy from nutrients.
NAD⁺ is also involved in the activity of enzymes that participate in cellular signaling, responses to DNA damage, and other biological processes.
Because NAD⁺ metabolism can change with age, researchers are investigating whether nutritional compounds that influence its availability might support aspects of healthy aging.
However, NAD⁺ levels vary across tissues and biological conditions. A measurement taken from blood does not necessarily reveal what is happening in every organ.
This is why researchers measure both NAD-related biomarkers and other outcomes when evaluating potential interventions.
What Is NMN, and Why Is It Being Studied?
NMN, or nicotinamide mononucleotide, is a naturally occurring compound involved in NAD⁺ biosynthesis.
The body uses several pathways to maintain NAD⁺ availability. NMN participates in one of the routes through which cells produce NAD⁺.
Researchers have therefore investigated whether oral NMN supplementation can increase measured NAD⁺ levels in humans.
That question is important, but it is only the starting point.
A supplement can influence a biological pathway without necessarily producing a measurable improvement in physical function, sleep, or long-term health.
The real value of human clinical trials is that they allow researchers to investigate these outcomes directly.
Inside the 2024 Human NMN Trial
The study, published in 2024, was designed as a randomized, double-blind, placebo-controlled trial.
It involved 60 older adults who received either NMN or placebo.
The NMN group consumed 250 mg daily for 12 weeks.
Researchers examined several outcomes, including:
- Blood NAD⁺ and related metabolites
- Physical performance
- Walking ability
- Sleep quality
- Stress-related measures
A randomized, placebo-controlled design helps researchers compare outcomes between participants receiving the intervention and those receiving a control.
However, the study was relatively small and lasted only 12 weeks. Its findings therefore need to be interpreted within those limits.
Study: Morifuji and colleagues, 2024.
Read the original human trial on PubMed
Finding 1: Blood NAD⁺ Increased
One of the clearest findings was an increase in blood NAD⁺ and related metabolites in the NMN group compared with placebo.
This is important because it demonstrates that oral NMN influenced a biological marker researchers specifically wanted to investigate.
But what does that mean in practical terms?
It establishes that NMN can affect measured NAD⁺ status under the conditions studied.
It does not automatically establish that NAD⁺ increased in every tissue, that mitochondrial function improved throughout the body, or that biological aging slowed.
Those are separate questions that require additional evidence.
The takeaway: The trial supports an effect on blood NAD⁺ biology, not a blanket claim of age reversal.
Finding 2: What Happened to Walking Performance?
The researchers evaluated physical performance using several tests, including a four-meter walking test and a stepping test.
After 12 weeks, participants receiving NMN had a significantly shorter four-meter walking time compared with the placebo group.
In simple terms, the NMN group completed that short walking test faster.
Researchers also reported an association between changes in walking time and changes in certain NAD-related measurements.
These findings are interesting because they connect a biochemical change with a measurable functional outcome.
However, an important distinction remains.
The primary stepping-test outcome did not significantly improve
The study's primary physical-function outcome was a stepping test. Researchers did not find a statistically significant difference between the NMN and placebo groups on that outcome.
The four-meter walking result was a secondary finding.
Secondary findings can help researchers identify promising effects for future investigation, but they should not be presented as though the study achieved every objective.
Nor does a faster four-meter walk automatically mean that a person has greater overall stamina, improved muscle strength, or reduced risk of age-related disability.
The takeaway: The walking result is an encouraging research signal, but it needs confirmation in larger studies.
Finding 3: Did NMN Improve Sleep Quality?
Sleep was another outcome investigated in the trial.
Researchers used the Pittsburgh Sleep Quality Index, or PSQI, a questionnaire that assesses different aspects of perceived sleep quality and related difficulties.
The study reported improvements in the global PSQI score and the daytime-dysfunction component in the NMN group compared with placebo.
This result attracted attention because sleep is an important part of healthy aging and everyday functioning.
However, the finding needs to be interpreted carefully.
A sleep-quality questionnaire is not the same as an objective measurement of every aspect of sleep. The trial also does not establish that NMN treats insomnia or other sleep disorders.
Because the study lasted only 12 weeks and included 60 participants, further research is needed to determine whether the findings can be replicated and how meaningful they are for different populations.
The takeaway: The study reported improvements in selected sleep-quality measures, but NMN is not established as a sleep treatment.
What Did the Trial Not Prove?
The most useful way to interpret a human study is to understand both its positive findings and its limitations.
The 2024 NMN trial did not prove that NMN:
- Reverses biological aging
- Extends human lifespan
- Prevents age-related diseases
- Improves every measure of physical performance
- Treats sleep disorders
- Produces the same results in every person
It also did not establish that the effects observed after 12 weeks persist over the long term.
These limitations do not make the study unimportant. They define what researchers can reasonably conclude from it.
The trial offers human evidence that NMN can increase blood NAD⁺ and related metabolites, alongside promising differences in selected walking and sleep outcomes.
That is a meaningful contribution to an evolving research field, without needing to turn it into a claim that NMN reverses aging.
Why Biomarkers and Real-World Outcomes Both Matter
The NMN trial illustrates an important principle in longevity science: researchers need to distinguish between biological markers and outcomes that directly reflect function.
Blood NAD⁺ measurements help researchers understand whether the intervention affects the pathway it is intended to influence.
Walking tests assess a specific aspect of physical performance.
Sleep questionnaires provide information about participants' reported sleep experiences.
Each measurement answers a different question.
If a biomarker improves, researchers still need to establish whether that change produces a meaningful health benefit.
If a physical-performance test improves, researchers need to determine whether the result is reproducible and clinically important.
And if an intervention produces positive results over 12 weeks, longer studies are needed to understand its durability and long-term safety.
This is why the most reliable interpretation considers the full study rather than focusing only on the most attractive result.
What Other Human NMN Research Adds
The 2024 study is part of a wider body of human research into NMN.
A 2022 randomized, double-blind, placebo-controlled study involving 30 healthy adults investigated 250 mg of NMN daily for 12 weeks. Researchers reported increased blood NAD⁺ concentrations.
Read the 2022 NMN study on PubMed
Other human trials have investigated different doses, populations, and outcomes.
Collectively, these studies help researchers understand whether oral NMN can influence NAD-related biomarkers and whether particular functional effects warrant further investigation.
However, the studies vary in design, participant characteristics, and measured outcomes. Results from one trial should not automatically be assumed to apply to every NMN formulation or every individual.
The overall picture is promising in some respects but still developing.
What Should You Look for When Choosing an NMN Supplement?
If you're exploring NMN, look beyond broad claims about energy, longevity, or reversing aging.
Start with the product's actual formulation.
Check the amount of NMN per serving, the complete ingredient list, recommended use, and available quality documentation.
Then compare the product with the clinical evidence.
For example, the 2024 trial discussed in this article used 250 mg daily for 12 weeks. A commercial product containing a different amount per serving does not automatically reproduce the study's results.
A product's ingredient identity and quality information are also separate from proof of clinical effectiveness.
A certificate of analysis can provide useful information about identity, purity, or tested contaminants, depending on what the document covers. It does not prove that the product reverses aging or guarantees better sleep and walking performance.
The best purchasing decision starts with understanding both what the product contains and what the research actually supports.
Explore Aeternum NMN
If the human research has sparked your interest in NAD⁺ biology, the next step is to review the product itself.
Aeternum NMN 500 mg Capsules provide β-nicotinamide mononucleotide in a clearly specified capsule formulation.
The product page includes the ingredient amount, suggested use, and available testing documentation. Reviewing these details lets you evaluate the formulation rather than relying solely on general claims about NMN.
It's important to distinguish the product's 500 mg serving from the 250 mg daily dose used in the 2024 trial. The trial's results cannot automatically be transferred to a different dose or commercial formulation.
Ready to Explore the Formulation?
Discover Aeternum NMN 500 mg Capsules. Review the ingredient details, serving information, and available quality documentation to decide whether this NAD⁺ precursor fits your healthy-aging goals.
EXPLORE AETERNUM NMN 500 MG CAPSULES
Product availability can vary by region. Check the product page for current stock and ordering options.
The Bottom Line
The 2024 human NMN trial delivered a nuanced result.
NMN increased blood NAD⁺ and related metabolites. Researchers also observed differences in four-meter walking performance and selected sleep-quality measures.
However, the primary stepping-test outcome did not show a statistically significant difference between groups.
The study does not prove that NMN reverses aging, extends lifespan, or reliably improves sleep and physical performance for everyone.
What it does provide is evidence that NMN can influence NAD-related biology in older adults, alongside functional findings that deserve further investigation.
For anyone considering NMN, the most useful approach is to understand the research, examine the actual formulation, and keep expectations aligned with the evidence.
Interested in NMN after reading the research? Explore Aeternum NMN, review the formulation and available quality information, and check current availability before making your decision.
Explore Aeternum NMN 500 mg Capsules
Research References
Morifuji M, Higashi S, Ebihara S, Nagata M. (2024).
Human randomized, double-blind, placebo-controlled study of NMN supplementation in older adults, examining blood NAD-related measures, walking performance, sleep quality, and other outcomes.
PMID: 38789831
Read the 2024 human NMN trial on PubMed
Okabe K, et al. (2022).
Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects.
PMID: 35479740
Read the 2022 human NMN trial on PubMed
Educational disclaimer: This article is for informational purposes only and is not intended to diagnose, treat, or prevent disease. Results from individual clinical trials should not automatically be attributed to every commercial NMN product. Consult a qualified healthcare professional if you have questions about whether a supplement is appropriate for you.